
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is well-positioned for growth with the commercial success of its three products, Afrezza, Furoscix, and V-Go, and the potential for additional indications within their pipeline. The company's strong partnerships with United Therapeutics and others, combined with multiple catalysts such as the potential approval of ReadyFlow and pediatric Afrezza, make it a compelling investment opportunity. Additionally, the recent positive commentary from UTHR on the potential for their Tyvaso DPI in IPF, as well as the pursuit of ralinepag DPI, further strengthens confidence in MannKind's royalty revenue stream. Overall, MannKind has a positive outlook with potential for significant revenue growth in the coming years.
Bears say
MannKind is reporting disappointing quarterly revenue and EPS numbers, with revenues falling short of analyst expectations and a negative EPS. The company has also not met previous revenue targets for Furoscix and is relying heavily on upcoming catalysts, such as the pediatric PDUFA for Afrezza and Phase 1b data for MNKD-201, to drive growth. However, there are concerns over the tolerability of MNKD-201 in IPF patients and potential delays in Phase 2. The company's cash and investment position has improved, but there are still uncertainties surrounding its future financial stability if these upcoming catalysts do not meet expectations.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares